{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:29:24Z","timestamp":1747178964002,"version":"3.40.5"},"reference-count":35,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2021,6,3]]},"DOI":"10.1080\/14740338.2021.1897566","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T09:42:08Z","timestamp":1614591728000},"page":"735-740","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Analysis of completeness for spontaneous reporting of disease-modifying therapies in multiple sclerosis"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7810-6831","authenticated-orcid":false,"given":"Ariane G. S.","family":"Araujo","sequence":"first","affiliation":[{"name":"Pharmaceutical Sciences Postgraduate Research Program, Health Sciences Sector, Federal University of Paran\u00e1, Curitiba, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa C.","family":"Lucchetta","sequence":"additional","affiliation":[{"name":"Department of Drugs and Medicines, Faculty of Pharmaceutical Sciences, S\u00e3o Paulo State University (UNESP), S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda S.","family":"Tonin","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Postgraduate Research Program, Health Sciences Sector, Federal University of Paran\u00e1, Curitiba, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Federal University of Paran\u00e1, Curitiba, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena H. L.","family":"Borba","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Federal University of Paran\u00e1, Curitiba, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4460-4044","authenticated-orcid":false,"given":"Astrid","family":"Wiens","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Federal University of Paran\u00e1, Curitiba, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30481-1"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4674"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.06.036"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2019.09.004"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518799598"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.3065"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1198775"},{"key":"cit0008","unstructured":"Nikolopoulou V, Siafis S, Milonas A, et al. eds. Safety of the newer disease-modifying agents for multiple sclerosis: disproportionality analysis in the FDA adverse events reporting system database. Dialogues in Clin Neurosci and Ment Health. 2019; 2(2): 81\u201393."},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2009041"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0131-x"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-015-0106-6"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2223-5"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-020-00969-7"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4247"},{"key":"cit0015","unstructured":"U.S. Food and Drug Administration (FDA). FDA adverse event reporting system (FAERS) quarterly data extract files. 2019. [cited 2019 Ago 10]. Available from: https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html."},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6048"},{"key":"cit0017","unstructured":"International Organization for Standardization-Country Codes- ISO 3166. 2019. [cited 2019 Sep 13]. Available from:http:\/\/www.iso.org\/iso\/home\/standards\/countrycodes.htm."},{"volume-title":"Medical dictionary for regulatory activities (MedDRA)","year":"2019","author":"International conference on harmonisation (ICH) of technical requirements for registration of pharmaceuticals for human use","key":"cit0018"},{"key":"cit0019","unstructured":"Drugs.com. Drug index a to z. 2019. [cited 2019 Oct 2]. Available from: http:\/\/www.drugs.com\/."},{"key":"cit0020","unstructured":"GenericDrugs. Therapeutic equivalent brand and generic drugs. 2019. [cited 2019 Oct 2]. Available from: http:\/\/www.ndrugs.com\/"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000700"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1080\/00220973.1995.9943797"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09835-y"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2020.02.022"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620909614"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3979"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-016-0463-4"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1559812"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1557(199601)5:1<1::AID-PDS203>3.0.CO;2-T"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0530-5"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2019.01.006"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.598"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-020-0392-9"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3397"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0237-9"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2021.1897566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T15:26:16Z","timestamp":1625498776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2021.1897566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6,3]]}},"alternative-id":["10.1080\/14740338.2021.1897566"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2021.1897566","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"type":"print","value":"1474-0338"},{"type":"electronic","value":"1744-764X"}],"subject":[],"published":{"date-parts":[[2021,3,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-10-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}